Media Home
UN Web TV
UN Audiovisual Library
UN PhotoWHO / COVID-19 UPDATE
Download
There is no media available to download.
Share
STORY: WHO / COVID-19 UPDATE
TRT:4:55
SOURCE: WHO
RESTRICTIONS: NOEN
LANGUAGE: ENGLISH / NATS
DATELINE: 15 FEBRUARY 2021, GENEVA, SWITZERLAND
1.Wide shot, press briefing room
2.SOUNDBITE (English) Dr Tedros Adhanom Ghebreyesus, WHO Director-General:
"The number of reported cases of COVID-19 globally has now declined for the fifth consecutive week. Last week saw the lowest number of reported weekly cases since October. So far this year, the number of weekly reported cases has fallen by almost half, from more than 5 million cases in the week of January 4 to 2.6 million cases in the week starting February 8 – just five weeks. This shows that simple public health measures work, even in the presence of variants."
3.Wide shot, press briefing room
4.SOUNDBITE (English) Dr Tedros Adhanom Ghebreyesus, WHO Director-General:
"Today WHO gave emergency use listing to two versions of the Oxford-AstraZeneca vaccine, giving the green light for these vaccines to be rolled out globally through COVAX. One of the vaccines is produced by SKBio in the Republic of Korea and the other is produced by the Serum Institute of India. Although both companies are producing the same vaccine, because they are made in different production plants, they required separate reviews and approvals. WHO emergency use listing assesses and assures the quality, safety and efficacy of COVID-19 vaccines, and is a prerequisite for vaccines to be distributed by COVAX."
5.Wide shot, press briefing room
6.SOUNDBITE (English) Deusdedit Mubangizi, Head, WHO Prequalification Unit:
"Today is a great day, especially for the COVAX. We started assessing these two vaccines hardly four weeks ago. But when you look at the map that has been shown in this various fora where
you have continents that have access to vaccines and then other countries that don't have, I think,any movement that increases capacity on the manufacturing and supply of vaccine is a great milestone for this world. If we are going to be safe, as the Director-General says, nobody will be safe unless everybody is safe. And today's announcement of two vaccines, versions of AstraZeneca, allows everybody to access vaccines"
7. Wide shot, press briefing room
8. SOUNDBITE (English) Dr Mike Ryan, EXD, WHO Health Emergencies Programme:
"This mission was envisaged as a collaborative effort under the under the World Health Assembly resolution, where obviously working with China, a sovereign state, a member state of WHO, to better understand the origins of the virus so as to learn lessons for the future. It was not as such an investigation of supposed wrongdoing or referring to any nonexistent investigatory powers that WHO might have. WHO does not possess the mandate to enter uninvited to any nation state."
9.Wide shot, press briefing room
10. SOUNDBITE (English) Dr Tedros Adhanom Ghebreyesus, WHO Director-General:
"Many times I hear that this is a WHO study or investigation. It's not. It's an independent study, a study which is composed of independent individuals from 10 institutions. And WHO's role here is coordination and that's what we should take into consideration too."
11. Wide shot, press briefing room
12. SOUNDBITE (English) Dr Tedros Adhanom Ghebreyesus, WHO Director-General:
"Yesterday, authorities in Guinea declared a separate outbreak of Ebola in the town of Gouecke, in the southeast of the country. So far, three cases have been confirmed, among six people who reported Ebola like-symptoms after attending a funeral in late January. Two have since died, while the other four are being treated in hospital. As you remember, Guinea was one of the three countries affected by the West Africa Ebola outbreak of 2014 to 2016, the largest Ebola outbreak on record. The outbreaks in Guinea and DRC are completely unrelated, but we face similar challenges in both."
13.Wide shot, press briefing room
The World Health Organization (WHO) today (15 Feb) listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use, giving the green light for these vaccines to be rolled out globally through COVAX. The vaccines are produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India.
WHO’s Emergency Use Listing (EUL) assesses the quality, safety and efficacy of COVID-19 vaccines and is a prerequisite for COVAX Facility vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.
The WHO EUL process can be carried out quickly when vaccine developers submit the full data required by WHO in a timely manner. Once those data are submitted, WHO can rapidly assemble its evaluation team and regulators from around the world to assess the information and, when necessary, carry out inspections of manufacturing sites.
In the case of the two AstraZeneca/Oxford vaccines, WHO assessed the quality, safety and efficacy data, risk management plans and programmatic suitability, such as cold chain requirements. The process took under four weeks.
The vaccine was reviewed on 8 February by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), which makes recommendations for vaccines’ use in populations (i.e. recommended age groups, intervals between shots, advice for specific groups such as pregnant and lactating women). The SAGE recommended the vaccine for all age groups 18 and above.
The AstraZeneca/Oxford product is a viral vectored vaccine called ChAdOx1-S [recombinant]. It is being produced at several manufacturing sites, as well as in the Republic of Korea and India. ChAdOx1-S has been found to have 63.09% efficacy and is suitable for low- and middle-income countries due to easy storage requirements.
Deusdedit Mubangizi, Head of WHO’s Prequalification Unit told reporters, “today is a great day, especially for the COVAX.”
He continued, “we started assessing these two vaccines hardly four weeks ago. But when you look at the map that has been shown in this various fora where you have continents that have access to vaccines and then other countries that don't have, I think,any movement that increases capacity on the manufacturing and supply of vaccine is a great milestone for this world.”
The emergency use listing (EUL) procedure assesses the suitability of novel health products during public health emergencies. The objective is to make medicines, vaccines and diagnostics available as rapidly as possible to address the emergency, while adhering to stringent criteria of safety, efficacy and quality. The assessment weighs the threat posed by the emergency as well as the benefit that would accrue from the use of the product against any potential risks.
The EUL pathway involves a rigorous assessment of late phase II and phase III clinical trial data as well as substantial additional data on safety, efficacy, quality and a risk management plan. These data are reviewed by independent experts and WHO teams who consider the current body of evidence on the vaccine under consideration, the plans for monitoring its use, and plans for further studies.
As part of the EUL process, the company producing the vaccine must commit to continue to generate data to enable full licensure and WHO prequalification of the vaccine. The WHO prequalification process will assess additional clinical data generated from vaccine trials and deployment on a rolling basis to ensure the vaccine meets the necessary standards of quality, safety and efficacy for broader availability.
WHO also listed the Pfizer/BioNTech vaccine for emergency use on 31 December 2020.
WHO’s Dr Mike Ryan also briefed the reporters. He said, "this mission was envisaged as a collaborative effort under the under the World Health Assembly resolution, where obviously working with China, a sovereign state, a member state of WHO, to better understand the origins of the virus so as to learn lessons for the future.”
He continued, “it was not as such an investigation of supposed wrongdoing or referring to any nonexistent investigatory powers that WHO might have. WHO does not possess the mandate to enter uninvited to any nation state."
Dr Tedros also said, "many times I hear that this is a WHO study or investigation. It's not. It's an independent study, a study which is composed of independent individuals from 10 institutions. And WHO's role here is coordination and that's what we should take into consideration too."
On Ebola, Dr Tedros said, on Sunday (14 Feb), “authorities in Guinea declared a separate outbreak of Ebola in the town of Gouecke, in the southeast of the country.”
He explained, “so far, three cases have been confirmed, among six people who reported Ebola like-symptoms after attending a funeral in late January. Two have since died, while the other four are being treated in hospital.”
Dr Tedros continued, “as you remember, Guinea was one of the three countries affected by the West Africa Ebola outbreak of 2014 to 2016, the largest Ebola outbreak on record. The outbreaks in Guinea and DRC are completely unrelated, but we face similar challenges in both."
